Autoimmune hepatitis after long-term methotrexate therapy for rheumatoid arthritis

Current Drug Safety

Volumn 6, Issue 3, 2011, Pages 197-200

  Moreno Otero, Ricardo ^a   García Buey, Luisa ^a   García Sanchez, Asunción ^b   Trapero Marugán, María ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

Author keywords

Autoimmune hepatitis; Corticosteroids; Drug induced autoimmunity; Immunological tolerance; Methotrexate; Rheumatoid arthritis

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE;

ADULT; ANAMNESIS; ARTICLE; ASTHENIA; AUTOIMMUNE HEPATITIS; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; JAUNDICE; LIVER BIOPSY; LONG TERM CARE; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; WEIGHT REDUCTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DRUG-INDUCED LIVER INJURY; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED;

EID: 80054706974     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488611797579221     Document Type: Article

References (26)

1. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131: 768-74.
2. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 22: 176-82.
3. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28.
4. Chakravarty K, MacDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008; 47: 924-5.
5. BSPAR Guidelines on methotrexate use in paediatric rheumatology. Approved by BSPAR executive committee in 2005. Available from: http://www.bspar.org.uk/pages/clinical_guidelines.asp (accessed March 2011).
6. Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: Guidelines for detection and prevention. Am J Gastroenterol 1988; 83: 1337-45.
7. Hawley DP, Camina N, Rangaraj S. British Isles survey of methotrexate monitoring practice during treatment of juvenile idiopathic arthritis. Semin Arthritis Rheum 2011; 40: 358-64.
8. Kremer JM, Kaye GI, Kaye NW, Ishak KG, Axiotis CA. Light and electron microscopic analysis of sequential liver biopsies samples for rheumatoid arthritis patients receiving long-term methotrexate therapy. Follow up over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995; 38: 1194-203.
9. Kremer JM, Furst DE, Weinblatt ME, Blotner SD. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23: 459-61.
10. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-4.
11. Quintin E, Scoacec J-Y, Marotte H, Miossec P. Rare incidence of methotrexate-specif lesions in liver biopsy of patients with arthritis and elevate liver enzymes. Arthritis Res Ther 2010; 12: R143.Epub 2010, Jul 16.
12. Chang C, Gershwin ME. Drugs and autoimmunity-A contemporary review and mechanistic approach. J Autoimmun 2010; 34: J266-75.
13. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996; 125: 558-598.
14. Medina J, Garcia-Buey L, Moreno-Otero R. Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment Pharmacol Ther 2003; 17: 1-10.
15. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176.
16. Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009; 50: 511-517.
17. Laffón A, Moreno A, Gutierrez-Bucero A, et al. Hepatic sinusoidal dilatation in rheumatoid arthritis. J Clin Gastroenterol 1989; 11: 653-7.
18. Abraham S, Begum S, Isemberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 2004; 63: 123-129.
19. Aithal GP. Medscape. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011; 7: 139-50.
20. Willkens RF, Leonard PA, Clegg DO, et al. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis 1990; 49: 591-593.
21. Jolivet J, Cowan CH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094-104.
22. Flax MH. Drug-induced autoimmunity. N Engl J Med 1974; 291: 414-415.
23. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001; 344: 655-664.
24. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008; 30: 5-11.
25. Germano V, Pichianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-20.
26. Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51: 2040-8.